Association and interaction analysis of metabolic syndrome and serumuric acid on diastolic heart failure

Journal of Endocrinological Investigation

Volumn 36, Issue 8, 2013, Pages 579-583

  Tang, Z H ^a   Fang, Z ^a   Zeng, F ^a   Li, Z ^a   Zhou, L ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Association; Chinese population; Diastolic heart failure; Interaction; Metabolic syndrome; Uric acid

Indexed keywords

URIC ACID;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIASTOLE; DIASTOLIC HEART FAILURE; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; URIC ACID BLOOD LEVEL;

ADULT; AGED; FEMALE; HEART FAILURE, DIASTOLIC; HUMANS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; URIC ACID; VENTRICULAR FUNCTION, LEFT;

EID: 84885621523     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/8851     Document Type: Article

References (30)

1. Aurigemma GP, Gaasch WH. Clinical practice. Diastolic heart failure. N Engl J Med 2004, 351: 1097-105.
2. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006, 355: 260-9.
3. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006, 355: 251-9.
4. Mogelvang R, Sogaard P, Pedersen SA, et al. Cardiac dysfunction assessed by echocardiographic tissue Doppler imaging is an independent predictor of mortality in the general population. Circulation 2009, 119: 2679-85.
5. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288: 2709-16.
6. Baldasseroni S, Urso R, Maggioni AP, et al. Prognostic significance of serum uric acid in outpatients with chronic heart failure is complex and related to body mass index: data from the IN-CHF Registry. Nutr Metab Cardiovasc Dis 2012, 22: 442-8.
7. Alimonda AL, Nunez J, Nunez E, et al. Hyperuricemia in acute heart failure. More than a simple spectator? Eur J Intern Med 2009, 20: 74-9.
8. Dawson J, Walters M. Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? Br J Clin Pharmacol 2006, 62: 633-44.
9. Cingolani HE, Plastino JA, Escudero EM, et al. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study. J Card Fail 2006, 12: 491-8.
10. Tsao PS, Niebauer J, Buitrago R, et al. Interaction of diabetes and hypertension on determinants of endothelial adhesiveness. Arterioscler Thromb Vasc Biol 1998, 18: 947-53.
11. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005, 366: 1059-62.
12. Dimitrijevic-Sreckovic V, Colak E, Djordjevic P, et al. Prothrombogenic factors and reduced antioxidative defense in children and adolescents with pre-metabolic and metabolic syndrome. Clin Chem Lab Med 2007, 45: 1140-4.
13. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008, 10: 933-89.
14. Peterson LR, Waggoner AD, Schechtman KB, et al. Alterations in left ventricular structure and function in young healthy obese women: assessment by echocardiography and tissue Doppler imaging. J Am Coll Cardiol 2004, 43: 1399-404.
15. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007, 115: 3213-23.
16. Ouwens DM, Diamant M. Myocardial insulin action and the contribution of insulin resistance to the pathogenesis of diabetic cardiomyopathy. Arch Physiol Biochem 2007, 113: 76-86.
17. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54: 1615-25.
18. de Simone G, Palmieri V, Bella JN, et al. Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. J Hypertens 2002, 20: 323-31.
19. Widlansky ME, Gokce N, Keaney JF jr, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003, 42 : 1149-60.
20. Santos RD. Uric acid and cardiovascular disease: how to solve another chicken or egg puzzle. Cardiology 2009, 114: 298-9.
21. Santos RD, Nasir K, Orakzai R, et al. Relation of uric acid levels to presence of coronary artery calcium detected by electron beam tomography in men free of symptomatic myocardial ischemia with versus without the metabolic syndrome. Am J Cardiol 2007, 99: 42-5.
22. Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 2006, 37: 1503-7.
23. Strasak A, Ruttmann E, Brant L, et al. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men. Clin Chem 2008, 54: 273-84.
24. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005, 16: 3553-62.
25. Sundstrom J, Sullivan L, D'Agostino RB, et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005, 45: 28-33.
26. Cowan BR, Young AA. Left ventricular hypertrophy and renin-angiotensin system blockade. Curr Hypertens Rep 2009, 11: 167-72.
27. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 2005, 25: 39-42.
28. Nakagawa T, Tuttle KR, Short RA, Johnson RJ. Hypothesis: fructoseinduced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol 2005, 1: 80-6.
29. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003, 42: 474-80.
30. Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2006, 290: F625-31.